Kancera

Kancera is a pharmaceutical company. The company develops pharmaceuticals that counteract injuries in acute and chronic inflammation. The products are developed primarily to counteract hyper-inflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe virus infections. Kancera is planning two Phase II clinical trials, in covid-19 and in cardiac patients. Kancera conducts research and development within Karolinska Institutet Science Park in Stockholm.